TLSA trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLSA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 9, 2026, Tiziana Life Sciences Ltd (TLSA) has a Wall Street consensus price target of N/A, based on estimates from 3 covering analysts. The company has a market capitalization of $44M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TLSA trades at a trailing P/E of -4.3x. Analysts expect EPS to grow +46.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 ARCTArcturus Therapeutics Holdings Inc. | $294M | $10.35 | $30.50 | +194.7% | Buy | — | 21 |
 PRAXPraxis Precision Medicines, Inc. | $7.7B | $277.62 | $611.69 | +120.3% | Buy | — | 18 |
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 AGIOAgios Pharmaceuticals, Inc. | $1.7B | $29.41 | $40.67 | +38.3% | Buy | — | 29 |
 FATEFate Therapeutics, Inc. | $214M | $1.84 | $5.63 | +206.8% | Buy | — | 31 |
 NKTRNektar Therapeutics | $1.2B | $37.26 | $121.33 | +225.6% | Buy | — | 33 |
 ADMAADMA Biologics, Inc. | $3.0B | $12.73 | $19.00 | +49.3% | Buy | 16.0x | 10 |
Quick answers to the most common questions about buying TLSA stock.
The consensus price target for TLSA is $N/A, close to the current price of $0.6888 (N/A% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
TLSA has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
TLSA's current price is $0.6888 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for TLSA, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
TLSA is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLSA stock forecast based on 3 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
TLSA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLSA analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.